This mutation is the most frequently found in thyroid cancers, accounting for more than 90% of oncogenic BRAF mutations, and drives thyroid tumorigenesis and progression by activating the mitogen-activated protein kinase/extracellular signal-regulated protein kinase (MAPK/ERK) signaling pathway [7,8]. The gene discussed is BRAF; the disease is thyroid cancer.